Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis

Patient Preference and Adherence, 11/27/2013

Etanercept is a soluble TNF receptor, with a mode of action and pharmacokinetics different to those of antibodies and distinctive efficacy and safety. Etanercept is less likely to induce reactivation of tuberculosis than the other anti–TNF drugs and it has been suggested that etanercept might be less immunogenic, especially in ankylosing spondylitis. Acute uveitis, Crohn’s disease, and sarcoidosis are other adverse events that have been rarely associated with etanercept therapy in patients with ankylosing spondylitis.

Print Article Summary Cat 2 CME Report